No photo of Sunandana Chandra

View Scopus Profile

Sunandana Chandra

  • 279 Citations
20122022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

I have an interest in the development of clinical trials, as well as studying novel biomarkers that may be used as prognostic and predictive tools in the management of melanoma and other advanced skin cancers, as well as cancer of unknown primary.

Training Experience

2011Residency, Case Western Reserve University Hospital
2014Fellowship, New York University Medical Center

Education/Academic qualification

MD, Michigan State University

… → 2008

MS, Michigan State University

… → 2003

Keywords

  • Cancer of Unknown Primary
  • Clinical Research
  • Drug Discovery
  • Melanoma
  • Skin Cancer

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Precision Medicine Medicine & Life Sciences
CTLA-4 Antigen Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2022

Prot #MK3475-716: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

Chandra, S.

DrugDev Inc., Merck Sharp & Dohme Corp.

10/25/18 → 10/25/21

Project: Research project

Prot #UWSC10294/NU UWF17D02: A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti‐PDL‐1 Antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases

Chandra, S.

University of Washington, EMD Serono Research & Development Institute, Inc.

4/1/18 → 5/31/22

Project: Research project

Prot #CO39722: A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma

Chandra, S.

Genentech, Inc.

11/21/17 → 1/1/22

Project: Research project

DRUG IMCGP100-202 -A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma

Chandra, S.

DrugDev Inc., Immunocore Limited

11/14/17 → 11/14/20

Project: Research project

Prot #DV3-MEL-01: A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Chandra, S.

PRA Health Sciences, Dynavax Technologies Corporation

10/3/17 → 10/3/20

Project: Research project

Research Output 2012 2019

  • 279 Citations
  • 14 Review article
  • 9 Article
  • 1 Chapter
  • 1 Short survey

Clinical characterization of colitis arising from anti-PD-1 based therapy

Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A. W., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 othersGibney, G. T., Rapisuwon, S., Eroglu, Z., Sullivan, R. & Johnson, D. B., Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.

Research output: Contribution to journal › Article

Colitis
Steroids
Therapeutics
Prednisone
Melanoma

Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma

Cavalcante, L., Chowdhary, A., Sosman, J. A. & Chandra, S., Oct 1 2018, In : American Journal of Clinical Dermatology. 19, 5, p. 657-670 14 p.

Research output: Contribution to journal › Review article

Melanoma
Vaccination
Clinical Trials
CD274 Antigen
Neoplasms
9 Citations

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Chae, Y. K., Arya, A., Iams, W., Cruz, M. R., Chandra, S., Choi, J. & Giles, F., May 16 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 39.

Research output: Contribution to journal › Review article

Non-Small Cell Lung Carcinoma
Immunotherapy
Melanoma
Clinical Trials
CTLA-4 Antigen
5 Citations

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J. E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., Rathmell, W. K., Ancell, K. K., Balko, J. M., Bowman, C., Davis, E. J., Chism, D. D., Horn, L., Long, G. V., Carlino, M. S., Lebrun-Vignes, B. & 7 othersEroglu, Z., Hassel, J. C., Menzies, A. M., Sosman, J. A., Sullivan, R. J., Moslehi, J. J. & Johnson, D. B., Dec 1 2018, In : JAMA Oncology. 4, 12, p. 1721-1728 8 p.

Research output: Contribution to journal › Article

CTLA-4 Antigen
Poisons
Meta-Analysis
Colitis
Pharmacovigilance

Immune Checkpoint Inhibitor Toxicity in 2018

Johnson, D. B., Chandra, S. & Sosman, J. A., Oct 23 2018, In : JAMA - Journal of the American Medical Association. 320, 16, p. 1702-1703 2 p.

Research output: Contribution to journal › Short survey